Dexmedetomidine infusion is associated with enhanced renal function after thoracic surgery

Area of Science:

• Anesthesiology
• Nephrology
• Pharmacology

Background:

• Post-thoracotomy pain management often involves epidural analgesia.
• Dexmedetomidine, a selective alpha-2 adrenergic agonist, is used for its sedative and analgesic properties.
• The effect of dexmedetomidine on perioperative renal function requires further investigation.

Purpose of the Study:

• To evaluate the impact of dexmedetomidine as an adjunct to epidural analgesia on urine flow rate and perioperative renal function.
• To test the hypothesis that dexmedetomidine enhances renal function in patients undergoing thoracotomy.

Main Methods:

• Post hoc analysis of a randomized, placebo-controlled, double-blind clinical trial involving 28 patients undergoing elective thoracotomy.
• Patients received a 24-hour intravenous infusion of either dexmedetomidine (0.4 mcg/kg/hr) or saline placebo.
• Renal parameters including urine output, calculated creatinine clearance (cCl(Cr)), serum creatinine (S(Cr)), and fractional change in S(Cr) (DeltaS(Cr)%) were recorded.

Main Results:

• The dexmedetomidine group showed significantly higher cumulative urine output at 4 and 12 hours postoperatively compared to the placebo group.
• Patients receiving dexmedetomidine had significantly better preserved perioperative renal function, indicated by a lower DeltaS(Cr)% and higher cCl(Cr).
• Fewer patients in the dexmedetomidine group received diuretic agents (14%) compared to the control group (43%).

Conclusions:

• Intravenous dexmedetomidine infusion, as an adjunct to epidural analgesia, induced diuresis in post-thoracotomy patients with normal preoperative renal function.
• The observed diuresis may be a reversal of tubular antidiuresis.
• Dexmedetomidine demonstrated a potential beneficial effect on glomerular filtration, as suggested by improved DeltaS(Cr)% and preserved cCl(Cr).